+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-10-05Number of Pages: 179

Biologics Market (Product - Monoclonal Antibodies, Vaccines, Cell Therapy, Recombinant Hormones/Proteins, and Gene Therapy; Applications - Infectious Diseases, Oncology, Immunology, and Autoimmune Diseases) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Biologics Market: Snapshot

The biologics market is expected to grow at an impressive pace during the forecast period. The gains will be driven by substantial investments in research and developmental activities in the biotechnology and pharmaceutical sector and the soaring demand for novel therapies for various rare diseases. Recent intensive researches in novel therapies and combination therapies have established the efficacy of biologics for treating a wide range of chronic diseases such as cancer, rheumatoid arthritis, macular degeneration, and hematological malignancies. The introduction of recombinant DNA technology has expanded the potential of the biologics market. The emergence of promising drug candidates has made several global and regional pharmaceutical players venture into the biologics market. The increasing rate of approval of biologics by various regulatory agencies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) has positively impacted the market.

The global biologics market is forecast to expand at a CAGR of 10.9% over the period 2016 – 2024. Maintaining a steady pace of growth, the market is anticipated to attain a valuation of US$479, 752 mn by the end of the forecast period.

Several players are making large investments in expanding their biologics facilities across major geographic regions to gain a stronghold in this market. Leading players are launching novel therapies approved by the FDA to gain a competitive edge over others. The top biotechnology and pharmaceutical companies are forging partnerships to consolidate their shares across various regions.

biologics market

North America Prominent Market; Expanding Scope of Biologics Makes Asia Pacific Lucrative

On the basis of geography, the global biologics market is segmented into Europe, North America, Latin America, the Middle East and Africa, and Asia Pacific. Of these, currently, North America leads the global biologics market and is anticipated to occupy a revenue share of over 40% by the end of 2024. The growth in this regional market is attributed to intensive R&D activities, innovative drug formulations, and a large number of clinical trials focused on large-molecule drug discovery. In addition, the promise of profitable returns due to the premium pricing of biologics will stimulate investment in the coming years.

However, owing to a wide patient base in need of novel therapies for chronic diseases and low cost involved in drug manufacturing, Asia Pacific has been brought to the forefront. The spiraling growth of the regional market is anticipated to outpace Europe as the second most prominent market for biologics. The Asia Pacific market is poised to expand at a tremendous CAGR of 15.6% during 2016–2024. Rise in favorable regulations for the approval of biologics has triggered the growth of the regional market. In addition, the influx of global pharmaceutical companies setting up their biologics production facilities in emerging markets, particularly China, is expected to propel the regional market.

Monoclonal Antibodies to Emerge as Most Lucrative Product Segment

On the basis of product type the global biologics market is segmented into monoclonal antibodies, vaccines, cell therapy, gene therapy, and recombinant hormones/vaccines. Amongst these, the monoclonal antibodies segment is expected to lead the market along the forecast period. The extensive growth is attributed to the increasing demand for personalized therapies in various regions. Furthermore, extensive researches in antibodies to discover targeted therapies for a variety of diseases, such as different types of cancers, infections, and various immunological disorders, are expected to propel the market. For instance, various researchers are studying the potential of monoclonal antibodies responsible for destroying cancer cells and cloning them so that they can be used for other patients to trigger positive immune responses. This segment is anticipated to rise at a CAGR of 11.9% during 2016–2024.

The market for vaccines and recombinant hormones/proteins is anticipated to register significant growth over the forecast period. However, competitive pricing of many vaccines and the large-scale expiry of biologic patents are likely to hinder the regional market. This segment is expected to witness an incremental rise in the global shares by the end of forecast period, driven by robust sales across developed and emerging markets.

The global biologics market is fairly fragmented with the presence of numerous global companies and several regional players. Few of the leading players in this market are AbbVie Inc., AstraZeneca, Amgen Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Merck & Co., Inc., and Novartis AG.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Biologics Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
     4.2.  Overview
     4.3. Market Opportunity Map
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. Global Biologics Market Analysis and Forecasts, 2014–2024
            4.5.1. Porter’s Analysis
            4.5.2. Supply Chain Analysis
                     4.5.2.1. Product Manufacturers
                     4.5.2.2. Product Distributors
                     4.5.2.3. End Users
            4.5.3. Market Revenue Projections (US$ Mn)
     4.9. Market Outlook

5. Global Biologics Market Analysis and Forecasts, By Product 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Global Biologics Market Value Share Analysis
     5.4. Market Value Forecast By Product , 2014–2024
            5.4.1. Monoclonal Antibodies
            5.4.2. Vaccines
            5.4.3. Recombinant Hormones/Proteins
            5.4.4. Cell Therapy
            5.4.5. Gene Therapy
            5.4.6. Others
     5.5. Market Attractiveness By Product

6. Global Biologics Market Analysis and Forecasts, By Application 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Biologics Market Value Share Analysis
     6.4. Market Value Forecast By Application , 2014–2024
            6.4.1. Oncology
            6.4.2. Infectious Diseases
            6.4.3. Immunology
            6.4.4. Autoimmune Diseases
            6.4.5. Others
     6.5. Market Attractiveness By Application

7. Global Biologics Market Analysis and Forecasts, By Region
     7.1. Key Findings
     7.2. Global Growth Scenario
     7.3. Market Value Forecast By Region
            7.3.1. North America 
            7.3.2. Europe 
            7.3.3. Asia Pacific 
            7.3.4. Latin America 
            7.3.5. MEA 
     7.4. Market Attractiveness By Country/Region

8. North America Biologics Market Analysis and Forecast
     8.1. Introduction/ Key findings
     8.2. Market Value Forecast By Product , 2014–2024
            8.2.1. Monoclonal Antibodies
            8.2.2. Vaccines
            8.2.3. Recombinant Hormones/Proteins
            8.2.4. Cell Therapy
            8.2.5. Gene Therapy
            8.2.6. Others
     8.3. Market Value Forecast By Application , 2014–2024
            8.3.1. Oncology
            8.3.2. Infectious Diseases
            8.3.3. Immunology
            8.3.4. Autoimmune Diseases
            8.3.5. Others
     8.4. Market Value Forecast By Country , 2014–2024
            8.4.1. US
            8.4.2. Canada
     8.5. Market Attractiveness Analysis 
            8.5.1. By Product 
            8.5.2. By Application 
            8.5.3. By Country

9. Europe Biologics Market Analysis and Forecast
     9.1. Introduction/Key Findings
     9.2. Market Value Forecast By Product , 2014–2024
            9.2.1. Monoclonal Antibodies
            9.2.2. Vaccines
            9.2.3. Recombinant Hormones/Proteins
            9.2.4. Cell Therapy
            9.2.5. Gene Therapy
            9.2.6. Others
     9.3. Market Value Forecast By Application , 2014–2024
            9.3.1. Oncology
            9.3.2. Infectious Diseases
            9.3.3. Immunology
            9.3.4. Autoimmune Diseases
            9.3.5. Others
     9.4. Market Value Forecast By Country , 2014–2024
            9.4.1. Germany 
            9.4.2. UK
            9.4.3. Spain
            9.4.4. France
            9.4.5. Italy 
            9.4.6. Rest of Europe
     9.5. Market Attractiveness Analysis 
            9.5.1. By Product 
            9.5.2. By Application 
            9.5.3. By Country

10. Asia Pacific Biologics Market Analysis and Forecast
     10.1. Introduction/Key Findings
     10.2. Market Value Forecast By Product , 2014–2024
            10.2.1. Monoclonal Antibodies
            10.2.2. Vaccines
            10.2.3. Recombinant Hormones/Proteins
            10.2.4. Cell Therapy
            10.2.5. Gene Therapy
            10.2.6. Others
     10.3. Market Value Forecast By Application , 2014–2024
            10.3.1. Oncology
            10.3.2. Infectious Diseases
            10.3.3. Immunology
            10.3.4. Autoimmune Diseases
            10.3.5. Others
     10.4. Market Value Forecast By Country , 2014–2024
            10.4.1. India
            10.4.2. China
            10.4.3. Japan
            10.4.4. Australia
            10.4.5. New Zealand
            10.4.6. Rest of Asia Pacific
     10.5. Market Attractiveness Analysis 
            10.5.1. By Product 
            10.5.2. By Application 
            10.5.3. By Country

11. Latin America Biologics Market Analysis and Forecast
     11.1. Introduction/Key Findings
     11.2. Market Value Forecast By Product , 2014–2024
            11.2.1. Monoclonal Antibodies
            11.2.2. Vaccines
            11.2.3. Recombinant Hormones/Proteins
            11.2.4. Cell Therapy
            11.2.5. Gene Therapy
            11.2.6. Others
     11.3. Market Value Forecast By Application , 2014–2024
            11.3.1. Oncology
            11.3.2. Infectious Diseases
            11.3.3. Immunology
            11.3.4. Autoimmune Diseases
            11.3.5. Others
     11.4. Market Value Forecast By Country , 2014–2024
            11.4.1. Brazil
            11.4.2. Mexico
            11.4.3. Rest of LATAM
     11.5. Market Attractiveness Analysis 
            11.5.1. By Product 
            11.5.2. By Application 
            11.5.3. By Country

12. MEA Biologics Market Analysis and Forecast
     12.1. Introduction/Key Findings
     12.2. Market Value Forecast By Product , 2014–2024
            12.2.1. Monoclonal Antibodies
            12.2.2. Vaccines
            12.2.3. Recombinant Hormones/Proteins
            12.2.4. Cell Therapy
            12.2.5. Gene Therapy
            12.2.6. Others
     12.3. Market Value Forecast By Application , 2014–2024
            12.3.1. Oncology
            12.3.2. Infectious Diseases
            12.3.3. Immunology
            12.3.4. Autoimmune Diseases
            12.3.5. Others
     12.4. Market Value Forecast By Country , 2014–2024
            12.4.1. South Africa
            12.4.2. Saudi Arabia
            12.4.3. UAE
            12.4.4. Rest of MEA
     12.5. Market Attractiveness Analysis 
            12.5.1. By Product 
            12.5.2. By Application 
            12.5.3. By Country

13. Competition Landscape
     13.1. Market Player – Competition Dashboard (By Tier and Size of companies)
     13.2. Blockbuster Drug Matrix
     13.3. Pipeline snapshot of Key Biological Therapies
     13.4. Company Profiles
            13.4.1. AbbVie Inc.
                     13.4.1.1. Company Overview
                     13.4.1.2. Financials
                     13.4.1.3. SWOT Analysis
                     13.4.1.4. Strategic Overview
            13.4.2. Amgen Inc.
                     13.4.2.1. Company Overview
                     13.4.2.2. Financials
                     13.4.2.3. SWOT Analysis
                     13.4.2.4. Strategic Overview
            13.4.3. AstraZeneca
                     13.4.3.1. Company Overview
                     13.4.3.2. Financials
                     13.4.3.3. SWOT Analysis
                     13.4.3.4. Strategic Overview
            13.4.4. Bayer AG
                     13.4.4.1. Company Overview
                     13.4.4.2. Financials
                     13.4.4.3. SWOT Analysis
                     13.4.4.4. Strategic Overview
            13.4.5. Eli Lilly and Company 
                     13.4.5.1. Company Overview
                     13.4.5.2. Financials
                     13.4.5.3. SWOT Analysis
                     13.4.5.4. Strategic Overview
            13.4.6. F. Hoffmann-La Roche Ltd. 
                     13.4.6.1. Company Overview
                     13.4.6.2. Financials
                     13.4.6.3. SWOT Analysis
                     13.4.6.4. Strategic Overview
            13.4.7. GlaxoSmithKline Plc. 
                     13.4.7.1. Company Overview
                     13.4.7.2. Financials
                     13.4.7.3. SWOT Analysis
                     13.4.7.4. Strategic Overview
            13.4.8. Johnson & Johnson Services, Inc. 
                     13.4.8.1. Company Overview
                     13.4.8.2. Financials
                     13.4.8.3. SWOT Analysis
                     13.4.8.4. Strategic Overview
            13.4.9. Merck & Co., Inc.
                     13.4.9.1. Company Overview
                     13.4.9.2. Financials
                     13.4.9.3. SWOT Analysis
                     13.4.9.4. Strategic Overview
            13.4.10. Novartis AG 
                     13.4.10.1. Company Overview
                     13.4.10.2. Financials
                     13.4.10.3. SWOT Analysis
                     13.4.10.4. Strategic Overview
            13.4.11. Pfizer Inc. 
                     13.4.11.1. Company Overview
                     13.4.11.2. Financials
                     13.4.11.3. SWOT Analysis
                     13.4.11.4. Strategic Overview
            13.4.12. Sanofi 
                     13.4.12.1. Company Overview
                     13.4.12.2. Financials
                     13.4.12.3. SWOT Analysis
                     13.4.12.4. Strategic Overview

List of Figures

Figure 01: Global Biologics Market Size (US$ Mn) Forecast, 2016–2024
Figure 02: Global Biologics Market Absolute $ Opportunity (US$ Mn), 2016?2024
Figure 03: Global Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 04: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 05: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 06: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 07: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 08: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 09: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 10: Global Biologics Market Attractiveness Analysis: by Product
Figure 11: Global Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 12: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 13: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 14: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 15: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 16: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 17: Global Biologics Market Attractiveness Analysis: by Applications
Figure 18: Global Biologics Market Value Share Analysis: by Region, 2016 and 2024
Figure 19: Global Biologics Market Attractiveness Analysis: by Region
Figure 20: North America  Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 21: North America Biologics Market Size and Y-o-Y Growth Projections, 2016-2024
Figure 22: North America Biologics Market Attractiveness Analysis: by Country
Figure 23: North America Biologics Market Value Share Analysis:  by Product, 2016 and 2024
Figure 24: North America Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 25: North America Biologics Market Value Share Analysis: by Country, 2016 and 2024
Figure 26: U.S. Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 27: U.S. Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 28: Canada Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 29: Canada Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 30: North America Biologics Market Forecast: by Product, 2016–2024
Figure 31: North America Biologics Market Forecast: by Application, 2016–2024
Figure 32: Europe Biologics Market Size (US$ Mn)  Forecast, 2016-2024
Figure 33: Europe Biologics Y-o-Y Growth Projections, 2016-2024
Figure 34: Europe Market Attractiveness Analysis: by Country
Figure 35: Europe Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 36: Europe Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 37: Europe Biologics Market Value Share Analysis: by Country, 2016 and 2024
Figure 38: Germany Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 39: Germany Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 40: U.K. Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 41: U.K. Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 42: France Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 43: France Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 44: Italy Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 45: Italy Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 46: Spain Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 47: Spain Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 48: Rest of Europe Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 49: Rest of Europe Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 50: Europe Biologics Market Forecast By Product Type, 2016–2024
Figure 51: Europe Biologics Market Forecast By Application, 2016–2024
Figure 52: Asia Pacific Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 53: Asia Pacific Biologics Market Size and Y-o-Y Growth Projections, 2016-2024
Figure 54: Asia Pacific Biologics Market Attractiveness Analysis: by Country, 2016-2024
Figure 55: Asia Pacific Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 56: Asia Pacific Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 57: Asia Pacific Biologics Market Value Share Analysis: by Country, 2016 and 2024
Figure 58: China Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 59: China Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 60: Japan Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 61: Japan Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 62: India Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 63: India Biologics Market Absolute $ Opportunity (US$ Mn),  2016-2024
Figure 64: Australia Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 65: Australia Biologics Market Absolute $ Opportunity (US$ Mn),  2016-2024
Figure 66: New Zealand Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 67: New Zealand Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 68: Rest of APAC Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 69: Rest of APAC Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 70: Asia Pacific Biologics Market Attractiveness Analysis: by Product, 2016–2024
Figure 71: Asia Pacific Biologics Market Attractiveness Analysis: by Applications, 2016–2024
Figure 72: Latin America Biologics Market Size (US$ Mn) Forecast, 2016–2024
Figure 73: Latin America Biologics Market Size and Y-o-Y Growth Projections, 2016–2024
Figure 74: Latin America Market Attractiveness Analysis: by Country
Figure 75: Latin America Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 76: Latin America Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 77: Latin America Market Value Share Analysis: by Country, 2016 and 2024
Figure 78: Brazil Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 79: Brazil Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 80: Mexico Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 81: Mexico Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 82: Rest of LATAM Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 83: Rest of LATAM Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 84: Latin America Biologics Market Attractiveness Analysis: by Product, 2016–2024
Figure 85: Latin America Biologics Market Attractiveness Analysis: by Applications, 2016–2024
Figure 86: MEA Biologics Market Size (US$ Mn) and Volume (Units) Forecast, 2016–2024
Figure 87: MEA Biologics Market Size and Y-o-Y Growth Projections, 2016–2024
Figure 88: MEA Biologics Market Attractiveness Analysis: by Country
Figure 89: Middle East and Africa Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 90: Middle East and Africa Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 91: MEA Biologics Market Value Share Analysis: by Country, 2016 and 2024
Figure 92: Saudi Arabia Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 93: Saudi Arabia Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 94: UAE Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 95: UAE Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 96: RSA Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 97: RSA Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 98: RSA Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 99: RSA Biologics Market Absolute $ Opportunity (US$ Mn),  2016-2024
Figure 100: MEA Biologics Market Attractiveness Analysis: by Product, 2016–2024
Figure 101: MEA Biologics Market Attractiveness Analysis: by Applications, 2016–2024

List of Tables

Table 01: Global Biologics Market Size (US$ Mn) Forecast: by Product, 2016–2024
Table 02: Global Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 03: Global Biologics Market Size (US$ Mn) Forecast: by Region, 2016-2024
Table 04: North America Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 05: North America Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 06: North America Biologics Market Size (US$ Mn) Forecast: by Country, 2016-2024
Table 07: Europe Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 08: Europe Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 09: Europe Biologics Market Size (US$ Mn) Forecast: by Country, 2016-2024
Table 10: Asia Pacific Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 11: Asia Pacific Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 12: Asia Pacific Biologics Market Size (US$ Mn) Forecast: by Country, 2016-2024
Table 13: Latin America Biologics Market Size (US$ Mn)  Forecast: by Product, 2016-2024
Table 14: Latin America Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 15: Latin America Biologics Market Size (US$ Mn) by Country, 2016–2024
Table 16: Middle East and Africa Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 17: Middle East and Africa Biologics Market Value (US$ Mn) Forecast: by Applications, 2016–2024
Table 18: Middle East & Africa Biologics Market Size (US$ Mn) Forecast: by Country, 2016–2024

Global Biologics Market: Scope and Methodology

This report provides forecast and analysis of the global biologics market on the global and regional levels. It provides historical data of 2015 along with forecast from 2016 to 2024 in terms of revenue (US$ Mn). The report also includes macroeconomic indicators along with an outlook for biologics revenue annually. It includes drivers and restraints of the global biologics market and their impact on each region during the forecast period. The report also comprises the study of applications and opportunities for biologics manufacturers. It also includes a detailed analysis by product type and supply chain analysis with a list of suppliers and industry stakeholders at each node in the supply chain.

In order to provide users of this report with a comprehensive view of the market, we have included detailed competitiveness analysis, key blockbuster products, clinical pipeline analysis and company players with unique propositions. The dashboard provides a comprehensive comparison of biologics manufacturers on parameters such as revenue sales, ranking of global players, strategic consolidations, i.e. mergers & acquisitions, licensing activities, as well as R&D activities. The study encompasses market attractiveness analysis, product type, application type, and region.

Global Biologics Market: Segmentation

The report includes the revenue generated from sales of biologics in all regions and important countries in these regions. By product, the global biologics market has been segmented into monoclonal antibodies, vaccines, recombinant hormones/vaccines, cell therapy, gene therapy and other products. By application type, the market is segmented into oncology, infectious diseases, immunology, auto-immune diseases, and other diseases. Furthermore, the global market is sub-segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Market numbers have been estimated based on the annual global and regional sales of key companies; annual production and the revenue of local players is derived from regional pricing trends. Market size and forecast for each segment have been provided in the context of global and regional markets. The global biologics market has been analyzed based on expected demand. Prices considered for the calculation of revenue are regional average prices obtained through primary quotes from numerous regional biologics manufacturers, suppliers, and distributors. All key end users have been considered, and potential applications have been estimated on the basis of secondary sources and feedback from primary respondents. Regional demand patterns have been taken into consideration while assessing the market for various products manufactured in different regions. Top-down approach has been used to estimate the biologics market by regions. Market numbers for global product type and application segments have been derived using the bottom-up approach, which is cumulative of each region’s demand. The company-level market share has been calculated on the basis of revenues reported by key manufacturers. The market has been forecast based on constant currency rates.

Several primary and secondary sources were consulted during the course of the study. Secondary sources include Factiva, World Bank, FDA, NCBI, Springer Journals, Google Books, Society Publications, Biotechnology Innovation Organization, Arthritis Foundation, British Society for Rheumatology and Hoover’s, as well as company annual reports and publications.

Global Biologics Market: Competitive Landscape

The report provides detailed competitive and company profiles of key participants operating in the global market. Key players in the global biologics market include AbbVie Inc., Amgen Inc, AstraZeneca, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi.

The market has been segmented as below:

Global Biologics Market – By Product

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Hormones/Proteins
  • Cell Therapy
  • Gene Therapy
  • Others

Global Biologics Market – By Applications

  • Oncology
  • Infectious Diseases
  • Immunology
  • Autoimmune Diseases
  • Others

Global Biologics Market – By Region

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • UK
    • Italy
    • Spain
    • France
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Middle East and Africa (MEA)
    • Saudi Arabia
    • UAE
    • RSA
    • Rest of MEA


 
 
Back To Top